AttendMe Owl Logo
AttendMe
Evidence Evolution
Cardiothoracic SurgeryCardiothoracic Surgery

How This Evidence Evolved

Mechanical vs Bioprosthetic Heart Valves

Balancing Durability Against Anticoagulation Risk in Prosthetic Valve Selection

21.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The Veterans Affairs randomized trial compared mechanical and bioprosthetic valves in 575 men undergoing aortic or mitral valve replacement. At 11 years, all-cause mortality probabilities were 0.57 and 0.62, respectively (P=0.57). Structural failure was observed only with bioprostheses, while bleeding complications were more frequent with mechanical valves.
Proof

Landmark RCTs and pivotal trials that established the evidence base

The 15-year final report of the VA trial (2000) and the 20-year report of the Edinburgh Heart Valve Trial (2003) provided long-term comparative data. At 15 years in the VA trial, all-cause mortality after AVR was lower with the mechanical valve (66% vs 79%, p=0.02) but not after MVR, largely because primary valve failure was virtually absent with mechanical valves; bioprosthetic failure occurred mainly in patients under 65 (AVR 26% vs 0%, p<0.001). In the Edinburgh trial (261 mitral, 211 aortic and 61 double replacements), 20-year survival did not differ between Bjork-Shiley and porcine valves (25.0% vs 22.6%, p=0.39), but survival with the original valve intact was better with Bjork-Shiley (23.5% vs 6.7%, p<0.0001) and major bleeding was more common (40.7% vs 27.9%, p=0.008). These trials established the tradeoff: durability versus bleeding risk.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Anticoagulation remains a central issue for mechanical valves. PROACT Xa tested apixaban against warfarin in patients with an On-X mechanical aortic valve implanted at least 3 months previously. The trial stopped early because of excess thromboembolic events with apixaban. Valve thrombosis or valve-related thromboembolism occurred at 4.2% versus 1.3% per patient-year; apixaban did not demonstrate noninferiority.
Now

Current standard of care and ongoing research directions

In California from 1996 through 2013, biologic prostheses increased from 11.5% to 51.6% of aortic and from 16.8% to 53.7% of mitral replacements. In PROACT Xa, valve thrombosis or valve-related thromboembolism occurred at 4.2% versus 1.3% per patient-year with apixaban versus warfarin. Vitamin K antagonists remain the only approved oral anticoagulants for preventing these events in patients with mechanical heart valves.

Landmark Trials in This Story

VA Cooperative Study1993Landmark

A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans Affairs Cooperative Study on Valvular Heart Disease

11-year mortality probability: mechanical 0.57 vs bioprosthetic 0.62 (P=.57); structural failure only in bioprostheses

New England journal of medicineRCTN=575
VA 15-Year Follow-up2000Landmark

Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial

All-cause mortality at 15 years — mechanical AVR 66% vs bioprosthetic 79% (p=0.02); primary valve failure <65y: bio 26% vs mech 0% (p<0.001)

Journal of the American College of CardiologyRCTN=575
Heart 2003

Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses.

Survival at 20 years: Bjork-Shiley 25.0% vs porcine 22.6% (log rank p=0.39); major bleeding 40.7% vs 27.9% (p=0.008)

HeartRandomised prospective trial at a tertiary cardiac centre, 1975-1979: 261 mitral, 211 aortic and 61 double valve replacements
PROACT Xa2023

Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve

Valve thrombosis or thromboembolism: apixaban 4.2% vs warfarin 1.3% per patient-year (difference 2.9, 95% CI 0.8-5.0); noninferiority not met

NEJM evidenceRCTN=863
Goldstone 2017 (California cohort)2017

Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement.

15-year mortality after AVR at age 45-54: biologic 30.6% vs mechanical 26.4% (HR 1.23, 95% CI 1.02-1.48, P=0.03)

N Engl J MedInverse-probability-weighted cohort study of primary aortic- or mitral-valve replacement in California, 1996-2013

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the main tradeoff between mechanical and bioprosthetic heart valves?+
Mechanical valves are durable but thrombogenic and require anticoagulation; bleeding is a key tradeoff. Bioprostheses are less thrombogenic but can deteriorate and require reoperation. At 15 years in the VA trial, primary valve failure after aortic replacement among patients under 65 was 0% with mechanical versus 26% with bioprosthetic valves.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026